Biosimilar Approval and Adoption Challenges
Accelerating the progress of biosimilars is key to lowering drug costs and improving patient access to potentially life-saving therapies.
Read MoreThe importance of a clinical-first approach to formulary development
The clinical efficacy of a drug must always take priority over any other considerations when developing formularies.
Read MoreCopay Assistance Strategy Reduces Financial Burdens for Plans And Patients
Innovative solution provides $0 member cost for costly specialty drugs while reducing plans’ costs
Read MoreTwo Ways to Assess the Holistic Value of Your Specialty Partner
Getting the most value out of your specialty drug management partner starts with asking the right questions.
Read MoreThe benefits of timely and actionable specialty reporting
A comprehensive suite of reporting tools—and the right specialty partner to interpret data—can be invaluable for plan sponsors.
Read MoreUnderstanding hereditary angioedema (HAE)
Breaking down what plan sponsors should know about HAE, its challenges and therapies.
Read MorePharmacy in Focus
See the future taking shape in pharmacy and how you can capitalize and prepare for 2024 and beyond.
Read MoreThe importance of utilization management within the medical benefit
The ever-evolving complexity of medications billed through the medical benefit requires continuous investment in processes to manage their increasingly high price tag.
Read MoreSimplifying medical benefit drug management complexities
An integrated approach to managing medically billed specialty drugs is key to optimizing cost savings and clinical outcomes.
Read MoreThree specialty drug trends to prepare for: Biosimilars, gene and cell therapies, cancer drugs
Biosimilars, gene and cell therapies, and cancer drugs are filling the specialty pipeline. Here are some insights for each category to help you stay informed. This topic was the focus of a breakout...
Read More